Viatris Announces Publication Of Phase 2b CARE Study Results For Cenerimod, Demonstrating Efficacy In Moderate-To-Severe Lupus
Viatris Announces Publication Of Phase 2b CARE Study Results For Cenerimod, Demonstrating Efficacy In Moderate-To-Severe Lupus
Viatris 宣佈發佈了 20億 CARE 研究結果，顯示 Cenerimod 在中度至重度狼瘡中的有效性。
Biomarker data from CARE study characterizing cenerimod's mechanism of action in systemic lupus erythematosus also published in the Annals of the Rheumatic Diseases
CARE研究的生物標誌物數據描述了cenerimod在系統性紅斑狼瘡中的作用機制，該數據也發表在《風溼病年鑑》上。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。